phenazopyridine hydrochloride (redirected from Prodium)

phen·a·zo·pyr·i·dine hydrochloride (fn-z-pr-dn)

n.

An oral analgesic used to treat urinary tract pain and urgency.

---

phenazopyridine hydrochloride

[fen′əzōpī′ridēn]

a urinary tract analgesic.

indications It is prescribed to reduce the pain of cystitis or other urinary tract infections or to relieve the pain following clinical procedures of the urinary tract.

contraindications Renal or hepatic insufficiency or known hypersensitivity to this drug prohibits its use.

adverse effects Among the more serious adverse effects are headache and GI disturbances.

---

phenazopyridine hydrochloride

AZO-Gesic, Azo-Standard, Baridium, Geridium, Phenazo (CA), Prodium, Pyridium, ReAzo, Uristat, Urogesic, UTI Relief

Pharmacologic class: Nonopioid analgesic

Therapeutic class: Urinary analgesic

Pregnancy risk category B

Action

Unknown. Thought to act locally on urinary tract mucosa to produce analgesic or anesthetic effects, relieving urinary burning, urgency, and frequency.

Availability

Tablets: 95 mg, 97.2 mg, 100 mg, 200 mg

⊘Indications and dosages

➣ Pain caused by lower urinary tract irritation

Adults: 200 mg P.O. t.i.d.

Children: 12 mg/kg P.O. daily in three divided doses

Contraindications

• Hypersensitivity to drug
• Renal insufficiency

Precautions

Use cautiously in:
• hepatitis
• pregnant or breastfeeding patients
• children younger than age 12.

Administration

• Give with or after meals.
• Discontinue after 2 days, as prescribed, when administering with antibiotics.

Route	Onset	Peak	Duration
P.O.	Unknown	Unknown	6-8 hr

Adverse reactions

CNS: headache

EENT: contact lens staining

GI: GI disturbances

GU: bright orange urine, renal toxicity

Hepatic: hepatotoxicity

Hematologic: hemolytic anemia , methemoglobinemia

Skin: rash, pruritus

Other: anaphylactoid-like reaction

Interactions

Drug-diagnostic tests. Bilirubin, glucose, ketones, protein, steroids: interference with urine tests based on spectrophotometry or color reactions

Patient monitoring

• Monitor patient for symptomatic improvement of urinary tract infection (UTI).
• Assess follow-up urine culture after antibiotic therapy ends.
☞ Monitor for yellowing of skin or sclera. This change may indicate drug accumulation caused by impaired renal excretion, warranting drug withdrawal.

Patient teaching

• Explain drug therapy and measures to help prevent UTI recurrence.
• Tell patient drug may discolor urine and tears and may stain clothing and contact lenses.
☞ Advise patient to contact prescriber promptly if symptoms don't improve or if skin or eyes become yellow.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.